Tromsø, Norway

Liv Marie Eike

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Liv Marie Eike: Innovator in Cancer Treatment

Introduction

Liv Marie Eike is a prominent inventor based in Tromsø, Norway. She has made significant contributions to the field of cancer treatment through her innovative research and development of new therapeutic compounds. With a total of three patents to her name, Eike is recognized for her work in advancing medical science.

Latest Patents

Eike's latest patents include groundbreaking inventions such as immune checkpoint inhibitor combinations. This invention provides a compound, preferably a peptide, designed to enhance the effectiveness of cancer therapies. Another notable patent focuses on chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics. This invention outlines a compound consisting of nine amino acids, with specific characteristics aimed at improving tumor treatment through combined administration with cytotoxic agents.

Career Highlights

Liv Marie Eike has established herself as a key figure in the biotechnology sector. Her work at Lytix Biopharma AS has positioned her at the forefront of cancer research. Eike's innovative approaches have the potential to transform treatment protocols and improve patient outcomes.

Collaborations

Eike collaborates with esteemed colleagues such as Oystein Rekdal and John Sigurd Mjoen Svendsen. These partnerships enhance her research efforts and contribute to the development of effective cancer therapies.

Conclusion

Liv Marie Eike's contributions to cancer treatment through her patents and collaborations highlight her role as an influential inventor in the medical field. Her work continues to pave the way for advancements in therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…